# Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs

> **NCT02943733** · PHASE1 · TERMINATED · sponsor: **University of Wisconsin, Madison** · enrollment: 18 (actual)

## Conditions studied

- Neuroendocrine Tumors
- Neoplasms
- Cancer
- Tumors

## Interventions

- **DRUG:** TAS-102
- **DRUG:** Temozolomide
- **DRUG:** Filgrastim
- **DRUG:** Pegfilgrastim

## Key facts

- **NCT ID:** NCT02943733
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-08-22
- **Primary completion:** 2020-11-07
- **Final completion:** 2022-01-31
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** closed per sponsor request, for slow enrollment
- **Last updated:** 2022-09-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02943733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02943733, "Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02943733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*